Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Credit agrmnt [a]
Director departure
Inv. presentation
Quarterly results
Acq. announced
|
|
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/09/2018 |
8-K/A
| Quarterly results |
| 07/21/2017 |
8-K/A
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
Docs:
|
"Indenture dated July 21, 2017, by and among Pernix Ireland Pain Limited, as issuer, the guarantors party thereto, and Wilmington Trust, National Association, as the trustee",
"Second Supplemental Indenture, by and among Pernix Therapeutics Holdings, Inc., Pernix Holdco 1, LLC, Pernix Holdco 2, LLC, Pernix Holdco 3, LLC and U.S. Bank, National Association as the trustee",
"Credit Agreement, by and among the lenders identified on the signature pages thereof, Cantor Fitzgerald Securities, as agent, Pernix Therapeutics Holdings, Inc., Pernix Therapeutics, LLC, Pernix Sleep, Inc., Cypress Pharmaceuticals, Inc., Gaine, Inc., Respicopea, Inc., Macoven Pharmaceuticals, L.L.C., and Hawthorn Pharmaceuticals, Inc., as borrowers, and the guarantors party thereto",
"Credit Agreement, by and among the lenders identified on the signature pages thereof, Cantor Fitzgerald Securities, as agent, and Pernix Ireland Pain Limited",
"Amendment No. 2 to the Interim Settlement Agreement by and among Pernix Therapeutics Holdings, Inc., Pernix Ireland Limited, Glaxo Group Limited, GlaxoSmithKline LLC, GlaxoSmithKline Intellectual Property Holdings Limited and GlaxoSmithKline Intellectual Property Management Limited",
"Registration Rights Agreement between Pernix Therapeutics Holdings, Inc., Pernix Ireland Pain Limited and 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P" |
|
| 07/28/2016 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 06/16/2015 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Independent Auditors",
"Audited Statements of Assets Acquired as of December 31, 2014 and 2013 and Statements of Revenues and Direct Expenses of the Zohyrdo ER® product line for the years ended December 31, 2014 and 2013 and the notes related thereto",
"Unaudited Statement of Assets Acquired as of March 31, 2015 and 2014 and Statements of Revenues and Direct Expenses of the Zohydro ER® product line for the three months ended March 31, 2015 and 2014, and the notes related thereto",
"Unaudited pro forma condensed combined balance sheet as of March 31, 2015 and unaudited pro forma condensed combined statements of operations and comprehensive income (loss) for the year ended December 31, 2014 and for the three months ended March 31, 2015, and the notes related thereto" |
|
| 03/10/2015 |
8-K/A
| Quarterly results |
| 10/09/2014 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of Cherry Bekaert LLP, Independent Registered Public Accounting Firm",
"Consent of PricewaterhouseCoopers LLP, Independent Accountants",
"Statement of Assets Acquired (audited) of the Treximet® product line as of August 20, 2014 and the notes related thereto",
"Statement of Revenues and Certain Direct Expenses of the Treximet® product line, including the notes related thereto, for each of the years in the three-year period ended December 31, 2013 (audited) and for the six months ended June 30, 2014 and 2013 (unaudited)",
"Unaudited pro forma condensed combined balance sheet as of June 30, 2014 and unaudited pro forma condensed combined statements of operations and comprehensive income (loss) for the year ended December 31, 2013 and for the six months ended June 30, 2014, and the notes related thereto" |
|
| 04/28/2014 |
8-K/A
| Submission of Matters to a Vote of Security Holders |
| 02/05/2013 |
8-K/A
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits|
Docs:
|
"Consent of Horne LLP, Independent Auditor",
"Cypress Pharmaceuticals, Inc. audited restated consolidated financial statements for the fiscal years ended December 31, 2011 and 2010",
"Cypress Pharmaceuticals, Inc. unaudited restated condensed consolidated interim financial statements for the nine-month periods ended September 30, 2012 and 2011",
"Unaudited restated pro forma condensed combined statement of operations for the nine months ended September 30, 2012, pro forma condensed combined statement of operations for the nine months ended September 30, 2012, pro forma condensed combined statement of operations for the year ended December 31, 2011 and the notes related thereto" |
|
| 06/04/2010 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 11/15/2004 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 11/15/2004 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 03/17/1997 |
8-K/A
| Form 8-K/A - Current report [Amend] |
|
|